Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

By sjmartinez • May 28, 2023

John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 May 24:S1556-0864(23)00574-9. doi: 10.1016/j.jtho.2023.05.015. Epub ahead of print. PMID: 37236398.

Tags: Adjuvant, EGFR, Hematology/Oncology, Non-small cell lung cancer, Osimertinib, Publications, safety

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]

Discussing lung cancer management options in the emergency department

Moghanaki D, Goldman J, Weingrow D, Hendey GW. Discussing lung cancer management options in the emergency department. Emerg Med J. 2026 Oct 30:emermed-2026-216560. doi: 10.1136/emermed-2026-216560.[...]

p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells

Boix de Jesus A, Dao HB, Imani A, Rodriguez GA, Shehata MS, Chandran RR, Fine SA, Lim SY, To M, Lofftus SY, Pedroncelli N, Eilber[...]